Americans spend almost $11 billion annually in medical care related to urologic diseases, and Medicare's share of the bill was $5.4 billion, according to a 5-year project issued by the National Institutes of Health that is now available in print and on CD.
Americans spend almost $11 billion annually in medical care related to urologic diseases, and Medicare's share of the bill was $5.4 billion, according to a 5-year project issued by the National Institutes of Health that is now available in print and on CD.
Of the $11 billion, treatment for five diseases-urinary tract infections, kidney stones, prostate and bladder cancers, and BPH (in order of dollars spent)-totalled $9.1 billion annually.
"This research sharply illustrates the immense burden of urologic diseases and the importance of studies to preempt disease processes and develop targeted therapies," NIH Director Elias A. Zerhouni, MD said.
"Urologic Diseases in America" is a comprehensive analysis of epidemiologic demographics, treatment patterns, and costs for a range of urologic diseases in children and adults. Multidisciplinary teams from UCLA and RAND Health and NIH's National Institute of Diabetes and Digestive and Kidney Diseases used data from the Centers for Medicare and Medicaid Services, the Agency for Healthcare Research and Quality, and the National Center for Health Statistics.
Among their findings:
"The data have broad implications for quality of care and access to care and helps to inform discussions about health care and research needs," said Urologic Diseases in America co-editor Mark S. Litwin, MD, MPH, of the UCLA David Geffen School of Medicine and School of Public Health.
Copies of "Urologic Diseases in America" are available at this week's AUA annual meeting. Visit the AUA Foundation booth, #2132. UDA books ($10) and CDs ($5) are also available from NIDDK's National Kidney and Urologic Diseases Information Clearinghouse: 1-800-891-5390 or (www.catalog.niddk.nih.gov); the fee is for shipping.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.